Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Amarin Corp Ads (AMRN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,978,803
  • Shares Outstanding, K 330,686
  • Annual Sales, $ 229,210 K
  • Annual Income, $ -116,450 K
  • 60-Month Beta 1.27
  • Price/Sales 26.92
  • Price/Cash Flow N/A
  • Price/Book 51.83

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate -0.04
  • Number of Estimates 3
  • High Estimate -0.03
  • Low Estimate -0.05
  • Prior Year -0.12
  • Growth Rate Est. (year over year) +66.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
16.51 +9.51%
on 05/15/19
19.67 -8.06%
on 05/29/19
+1.30 (+7.75%)
since 05/14/19
3-Month
16.20 +11.60%
on 05/13/19
21.50 -15.91%
on 03/18/19
-2.49 (-12.11%)
since 03/14/19
52-Week
2.35 +669.36%
on 07/31/18
23.33 -22.50%
on 11/06/18
+14.83 (+456.31%)
since 06/14/18

Most Recent Stories

More News
CORRECTING and REPLACING -- Amarin to Present Findings Regarding Challenges of Current Treatment Options in Reducing Cardiovascular Risks for Diabetes Patients, Even for Those With Controlled Cholesterol Levels, at Annual American Diabetes Association (ADA) Meeting

Approximately 10 Million People with Diabetes Are at Elevated Risk of Cardiovascular Disease

AMRN : 18.08 (-3.11%)
Amarin to Present Findings Regarding Challenges of Current Treatment Options in Reducing Cardiovascular Risks for Diabetes Patients, Even for Those With Controlled Cholesterol Levels, at Annual American Diabetes Association (ADA) Meeting

-- Approximately 10 Million People with Diabetes Are at Elevated Risk of Cardiovascular Disease

AMRN : 18.08 (-3.11%)
Amarin to Present at the Goldman Sachs 40th Annual Global Healthcare Conference

Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that John F. Thero, Amarin's...

AMRN : 18.08 (-3.11%)
Amarin Rises on Priority Review for Vascepa Label Expansion

Amarin's (AMRN) label expansion application for hypertriglyceridemia drug, Vascepa, gets priority review from the FDA.

ANIK : 39.77 (-1.51%)
AMRN : 18.08 (-3.11%)
AMGN : 176.08 (-0.36%)
SNY : 42.47 (-0.49%)
Amarin to Present at the Jefferies 2019 Healthcare Conference

Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that John F. Thero, Amarin's...

AMRN : 18.08 (-3.11%)
Vascepa(R) to Be Featured in Multiple Scientific Sessions at the National Lipid Association Annual Meeting

Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on improving cardiovascular health, today announced that Vascepa(R) (icosapent ethyl) and its landmark cardiovascular outcomes trial,...

AMRN : 18.08 (-3.11%)
Options Traders Expect Huge Moves in Amarin (AMRN) Stock

Investors need to pay close attention to Amarin (AMRN) stock based on the movements in the options market lately.

AMRN : 18.08 (-3.11%)
Amarin (AMRN) Beats Estimates for Earnings & Revenues in Q1

Amarin (AMRN) surpasses estimates for earnings and sales in the first quarter of 2019.

AMRN : 18.08 (-3.11%)
New Drug Submission Filed for Vascepa(R) with Health Canada

Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on improving cardiovascular health, today announced that its licensee in Canada, HLS Therapeutics Inc. (TSX:HLS), has filed a New...

AMRN : 18.08 (-3.11%)
HLS.TO : 15.60 (-0.64%)
What's in the Cards for Amarin (AMRN) This Earnings Season?

Amarin's (AMRN) cardiovascular drug, Vascepa to drive sales in the first quarter.

AMRN : 18.08 (-3.11%)
INCY : 77.71 (+1.75%)
GILD : 66.36 (-0.94%)
ADRO : 1.79 (-3.76%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

See More Share

Trade AMRN with:

Business Summary

Amarin Corporation plc is a global pharmaceutical group which develops innovative pharmaceutical products across a range of therapeutic areas utilizing its proprietary advanced oral and transdermal drug delivery technologies.

See More

Key Turning Points

2nd Resistance Point 19.23
1st Resistance Point 18.66
Last Price 18.08
1st Support Level 17.70
2nd Support Level 17.31

See More

52-Week High 23.33
Last Price 18.08
Fibonacci 61.8% 15.32
Fibonacci 50% 12.84
Fibonacci 38.2% 10.36
52-Week Low 2.35

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar